175 related articles for article (PubMed ID: 36072540)
1. Therapeutic drug monitoring and
Chen X; Xiao Y; Li H; Huang Z; Gao J; Zhang X; Li Y; Van Timothee BM; Feng X
Transl Pediatr; 2022 Aug; 11(8):1311-1322. PubMed ID: 36072540
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole.
Mafuru M; Wu S; Mayala H; Msengwa Z; Phillip A; Mgone C
Pharmgenomics Pers Med; 2021; 14():1379-1389. PubMed ID: 34754219
[TBL] [Abstract][Full Text] [Related]
3. Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.
García-García I; Dapía I; Montserrat J; Martinez de Soto L; Bueno D; Díaz L; Queiruga J; Rodriguez Mariblanca A; Guerra-García P; Ramirez E; Frías J; Pérez Martínez A; Carcas-Sansuan AJ; Borobia AM
Front Pharmacol; 2021; 12():717932. PubMed ID: 34744712
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
[TBL] [Abstract][Full Text] [Related]
5. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a mathematical prediction model for voriconazole stable maintenance dose: a prospective study.
Zhou L; Li M; Li H; Guo Z; Gao Y; Zhang H; Qin F; Sang Z; Xing Q; Cheng L; Cao W
Front Cell Infect Microbiol; 2023; 13():1157944. PubMed ID: 37565064
[TBL] [Abstract][Full Text] [Related]
8. Combined Effect of
Chen J; Wu Y; He Y; Feng X; Ren Y; Liu S
Front Pediatr; 2022; 10():846411. PubMed ID: 35386257
[TBL] [Abstract][Full Text] [Related]
9. Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients.
Takahashi T; Smith AR; Jacobson PA; Fisher J; Rubin NT; Kirstein MN
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988816
[TBL] [Abstract][Full Text] [Related]
10. Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.
Fujita Y; Araki T; Okada Y; Aomori T; Shimizu R; Tomizawa T; Hiromura K; Nojima Y; Nakamura T; Yamamoto K
J Clin Pharm Ther; 2013 Feb; 38(1):74-6. PubMed ID: 22971159
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity.
Shoji K; Hikino K; Saito J; Matsui T; Utano T; Takebayashi A; Tomizawa D; Kato M; Matsumoto K; Ishikawa T; Kawai T; Nakamura H; Miyairi I; Terao C; Mushiroda T
J Infect Chemother; 2024 Jun; ():. PubMed ID: 38897411
[TBL] [Abstract][Full Text] [Related]
12. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.
Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S
J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
14. [CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients].
Qu HL; Guo DD; Xu T; Li Z; Yin J; Tian XP; Kong DQ; Zhu XM; Miao LY; Wu DP; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2018 Mar; 39(3):202-206. PubMed ID: 29562464
[No Abstract] [Full Text] [Related]
15. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
16. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
[TBL] [Abstract][Full Text] [Related]
17. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases.
Shen K; Gu Y; Wang Y; Lu Y; Ni Y; Zhong H; Shi Y; Su X
Ther Adv Drug Saf; 2022; 13():20420986221127503. PubMed ID: 36225945
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.
Sienkiewicz B; Urbaniak-Kujda D; Dybko J; Dryś A; Hurkacz M; Wróbel T; Wiela-Hojeńska A
Pathol Oncol Res; 2018 Jul; 24(3):541-545. PubMed ID: 28685218
[TBL] [Abstract][Full Text] [Related]
20. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
Chuwongwattana S; Jantararoungtong T; Chitasombat MN; Puangpetch A; Prommas S; Dilokpattanamongkol P; Watcharananan SP; Sukasem C
Drug Metab Pharmacokinet; 2016 Apr; 31(2):117-22. PubMed ID: 26861072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
